blindness and glp 1 People Going Blind From GLP-1: Risks, Evidence Protection – Bolt Pharmacy Ocular Effects of GLP-1 Receptor

Description

Specialists in obesity medicine play a crucial role in creating treatment strategies that help patients lose weight while maintaining lean muscle mass

Ozempic is a once-weekly injectable form of semaglutide used to improve glycemic control in adults with T2DM and, when used in conjunction with diet and exercise, can reduce the risk of major cardiovascular events in individuals with established CVD.7 Typical dosing for Ozempic begins at 0.25 mg once weekly for four weeks to minimize gastrointestinal (GI) side effects, followed by 0.5 mg weekly, with the option to increase to 1 mg or 2 mg weekly depending on clinical response and glycemic control needs.7 Ozempic is often prescribed off-label for weight loss